Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study

Graboski C L, Gray D S, Burnham R S

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
16202527

DOI
10.1016/j.pain.2005.08.012

Indexing Status
Subject indexing assigned by NLM

MeSH
Anesthetics, Local /administration & dosage /economics /therapeutic use; Botulinum Toxins, Type A /administration & dosage /economics /therapeutic use; Bupivacaine /administration & dosage /economics /therapeutic use; Cross-Over Studies; Double-Blind Method; Drug Costs; Facial Pain /diagnosis /drug therapy /physiopathology; Female; Health Care Costs; Humans; Injections, Intramuscular; Male; Middle Aged; Muscle, Skeletal /drug effects /physiopathology; Pain Measurement; Physical Examination; Physical and Rehabilitation Medicine /methods; Treatment Outcome

AccessionNumber
22005001771

Date bibliographic record published
23/12/2005